Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated,
Li-Hua Chen1, Jing Fang, Huaixing Li
1Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and Graduate School of the Chinese Academy of Sciences, Shanghai, China.
Abstract:
The mammalian lignan enterolactone is a major metabolite of plant-based lignans that has been shown to inhibit the growth and development of prostate cancer. However, little is known about the mechanistic basis for its anticancer activity. In this study, we report that enterolactone selectively suppresses the growth of LNCaP prostate cancer cells by triggering apoptosis. Mechanistic studies showed that enterolactone-induced apoptosis was characterized by a dose-dependent loss of mitochondrial membrane potential, release of cytochrome c and cleavage of procaspase-3 and poly(ADP-ribose)-polymerase (PARP). Caspase dependence was indicated by the ability of the pan-caspase inhibitor z-VAD-fmk to attenuate enterolactone-mediated apoptosis. Mechanistic studies suggested roles for Akt, GSK-3beta, MDM2, and p53 in enterolactone-dependent apoptosis. Our findings encourage further studies of enterolactone as a promising chemopreventive agent against prostate cancer.
Insights
Enterolactone, a metabolite of plant lignans, selectively kills prostate cancer cells by inducing apoptosis. This process involves mitochondrial dysfunction and caspase activation, suggesting its potential as a cancer preventive agent.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Enterolactone is a mammalian lignan metabolite derived from plant lignans.
- Enterolactone has demonstrated inhibitory effects on prostate cancer growth and development.
- The precise mechanisms underlying enterolactone's anticancer activity remain largely unelucidated.
Purpose of the Study:
- To investigate the mechanistic basis of enterolactone's selective suppression of prostate cancer cell growth.
- To elucidate the role of apoptosis in enterolactone's anticancer effects.
- To identify key molecular players involved in enterolactone-induced apoptosis.
Main Methods:
- Utilized LNCaP prostate cancer cells to assess enterolactone's effects.
- Quantified mitochondrial membrane potential and cytochrome c release.
- Analyzed procaspase-3 and poly(ADP-ribose)-polymerase (PARP) cleavage.
- Employed a pan-caspase inhibitor (z-VAD-fmk) to confirm caspase dependence.
- Investigated the involvement of signaling pathways including Akt, GSK-3beta, MDM2, and p53.
Main Results:
- Enterolactone selectively inhibited the growth of LNCaP prostate cancer cells.
- Enterolactone triggered apoptosis, evidenced by dose-dependent mitochondrial membrane potential loss and cytochrome c release.
- Cleavage of procaspase-3 and PARP confirmed apoptosis induction.
- Enterolactone-mediated apoptosis was caspase-dependent.
- Akt, GSK-3beta, MDM2, and p53 were implicated in the apoptotic process.
Conclusions:
- Enterolactone induces apoptosis in prostate cancer cells via mitochondrial pathways and caspase activation.
- The study identifies key molecular mediators of enterolactone's action.
- Enterolactone shows promise as a chemopreventive agent for prostate cancer, warranting further investigation.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Apoptosis
The Extrinsic Apoptotic Pathway
Cellular Injury V: Apoptosis and Autophagy
Caspases
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
